Skip to content

EU labeling rules for drugs and biologics

Oak
A small iridescent lizard-bird with a collar of coloured frills, one frill unfolded and hanging down the front of its plinth.

Directive 2001/83/EC fixes the particulars that must appear on the outer packaging of a medicinal product and, where there is no outer packaging, on the immediate packaging.1 What may be claimed is bounded by the summary of product characteristics. The competent authority refuses the marketing authorisation where the labelling or the package leaflet fails to comply with Title V or departs from the particulars listed in that summary.1 The same Title sets the content and order of the package leaflet, the language in which it appears and the testing it must undergo.

Particulars required on the outer packaging

Article 54 lists the particulars for the outer packaging of a medicinal product. Where there is no outer packaging, the same list applies to the immediate packaging.1 The required particulars are:

  • the name of the medicinal product followed by its strength and pharmaceutical form. An indication of whether it is intended for babies, children or adults is given where appropriate. Where the product contains up to three active substances, the international non-proprietary name or the common name if no INN exists is given.
  • a statement of the active substances expressed qualitatively and quantitatively, per dosage unit or according to the form of administration for a given volume or weight, using their common names.
  • the pharmaceutical form and the contents by weight, by volume or by number of doses.
  • a list of those excipients known to have a recognised action or effect and included in the detailed guidance published pursuant to Article 65.
  • the method of administration and the route of administration if necessary. Space is provided for the prescribed dose to be indicated.
  • a special warning that the product must be stored out of the reach and sight of children.
  • a special warning where one is necessary for the product.
  • the expiry date in clear terms, expressed as month and year.
  • special storage precautions, if any.
  • specific precautions relating to the disposal of unused product or derived waste where appropriate, with reference to any appropriate collection system in place.
  • the name and address of the marketing authorisation holder and, where applicable, the name of the representative appointed by the holder.
  • the number of the authorisation for placing the product on the market.
  • the manufacturer’s batch number.
  • instructions for use, in the case of non-prescription medicinal products.
  • safety features, for medicinal products other than the radiopharmaceuticals referred to in Article 54a(1).1

The excipient rule takes a wider form for certain presentations. Where the product is injectable, or a topical or eye preparation, all excipients must be stated.1

The safety features under point (o) carry two functions. They enable wholesale distributors and persons authorised or entitled to supply medicinal products to the public to verify the authenticity of the product and to identify individual packs. Point (o) also requires a device allowing verification of whether the outer packaging has been tampered with.1

Immediate packaging, blister packs and small units

Article 55 governs what appears on the container inside the carton. As a general rule, the particulars laid down in Article 54 appear on immediate packagings.1 Two reduced sets apply to defined pack types.

Blister packs placed in an outer packaging that complies with Articles 54 and 62 carry at least the name of the medicinal product as laid down in Article 54(a), the name of the marketing authorisation holder, the expiry date and the batch number.1 Small immediate packaging units on which the particulars laid down in Articles 54 and 62 cannot be displayed carry at least the following.1

  • the name of the product as laid down in Article 54(a)
  • if necessary, the route of administration
  • the method of administration
  • the expiry date
  • the batch number
  • the contents by weight, by volume or by unit

Article 56 applies a single presentation standard to all of this material. The particulars referred to in Articles 54, 55 and 62 must be easily legible, clearly comprehensible and indelible.1

Content and order of the package leaflet

The package leaflet is drawn up in accordance with the summary of the product characteristics, and Article 59(1) prescribes the order of its contents.1 The sequence runs as follows:

  • identification of the product. This gives the name with strength and pharmaceutical form. It gives the target age group where appropriate. It gives the common name where the product has a single active substance under an invented name. It gives the pharmaco-therapeutic group or type of activity in terms easily comprehensible for the patient.
  • the therapeutic indications.
  • the information necessary before the product is taken. This covers contra-indications and appropriate precautions for use. It covers interactions with other medicinal products and other interactions such as alcohol, tobacco or foodstuffs. It also covers special warnings.
  • the necessary and usual instructions for proper use. These include dosage, method and route of administration and frequency. They include, as appropriate, duration of treatment and action in case of overdose. They also include what to do when doses have been missed, risk of withdrawal effects and a recommendation to consult the doctor or pharmacist.
  • a description of the adverse reactions which may occur under normal use and, if necessary, the action to be taken.
  • a reference to the expiry date on the label, with a warning against use after that date. Special storage precautions are given where appropriate. A warning about visible signs of deterioration is given if necessary. The full qualitative composition and the quantitative composition in active substances are given using common names. The pharmaceutical form and content are given for each presentation. The name and address of the marketing authorisation holder and any appointed representatives are given, together with the name and address of the manufacturer.
  • where the product is authorised under Articles 28 to 39 under different names in the Member States concerned, a list of the names authorised in each Member State.
  • the date on which the package leaflet was last revised.1

Two standardised texts sit alongside that sequence. For products included in the list referred to in Article 23 of Regulation (EC) No 726/2004, the leaflet carries the statement “This medicinal product is subject to additional monitoring”, preceded by the black symbol referred to in that Article and followed by an appropriate standardised explanatory sentence.1 For all medicinal products, the leaflet includes a standardised text asking patients to communicate any suspected adverse reaction to a doctor, pharmacist or healthcare professional, or directly to the national spontaneous reporting system referred to in Article 107a(1), and specifying the available reporting routes.1

Article 59(2) shapes the pre-use information block. It must take into account the particular condition of certain categories of users, such as children, pregnant or breastfeeding women, the elderly and persons with specific pathological conditions. It must mention possible effects on the ability to drive vehicles or operate machinery where appropriate, and list those excipients knowledge of which is important for safe and effective use and which are included in the detailed guidance published pursuant to Article 65.1

Readability testing is a legal requirement rather than a recommendation. Article 59(3) states that the package leaflet must reflect the results of consultations with target patient groups, to ensure that it is legible, clear and easy to use.1

Claims, symbols and the promotional exclusion

The summary of product characteristics is the outer limit of what the pack and the leaflet may say. Article 61(2) requires the competent authority to refuse the marketing authorisation where the labelling or the package leaflet is not in accordance with the particulars listed in that summary.1 Therapeutic indications reach the patient through the leaflet under Article 59(1)(b), in the form authorised.1

Article 62 allows additional material within limits. The outer packaging and the package leaflet may include symbols or pictograms designed to clarify certain information mentioned in Articles 54 and 59(1), and other information compatible with the summary of the product characteristics which is useful for the patient. Article 62 excludes any element of a promotional nature from both the outer packaging and the leaflet.1

The EU package leaflet is a user-directed document. Article 63(2) requires it to be written and designed so as to be clear and understandable, enabling users to act appropriately, when necessary with the help of health professionals.1

Language of the labelling and the leaflet

Article 63(1) requires the particulars for labelling listed in Articles 54, 59 and 62 to appear in an official language or official languages of the Member State where the product is placed on the market, as specified by that Member State.1 Multilingual packs are permitted, provided that the same particulars appear in all the languages used.1 For certain orphan medicinal products, the particulars listed in Article 54 may appear in only one of the official languages of the Community, on reasoned request.1

The leaflet carries the same language obligation and must be clearly legible in the official language or languages of the Member State of placing on the market.1 Printing the leaflet in several languages is permitted where the same information is given in all of them.1

Article 63(3) provides two exemptions. Where the product is not intended to be delivered directly to the patient, or where there are severe problems in respect of its availability, competent authorities may grant an exemption from the obligation that certain particulars appear on the labelling and in the package leaflet. They may also grant a full or partial exemption from the language obligation. Both exemptions are subject to the measures the authorities consider necessary to safeguard human health.1

Mock-ups, patient testing and later changes

Article 61(1) governs what the applicant files. One or more mock-ups of the outer packaging and the immediate packaging, together with the draft package leaflet, are submitted to the authorities competent for authorising marketing when the marketing authorisation is requested. The results of assessments carried out in cooperation with target patient groups are also provided to the competent authority.1

Changes after authorisation follow one of two routes. Proposed changes to an aspect of the labelling or the leaflet covered by Title V that are not connected with the summary of product characteristics are submitted to the competent authorities. Where the authorities have not opposed the proposed change within 90 days of the request being introduced, the applicant may put the change into effect.1

Regulatory clearance does not shift responsibility. Article 61(4) states that the absence of a refusal under Article 61(2), or of opposition to a change under Article 61(3), does not alter the general legal liability of the manufacturer and the marketing authorisation holder.1

Questions people also ask

What must appear on a blister pack inside an EU carton?

Where the blister pack sits in an outer packaging that complies with Articles 54 and 62, Article 55(2) requires at least four particulars on the blister itself. These are the name of the medicinal product as laid down in Article 54(a), the name of the holder of the marketing authorisation, the expiry date and the batch number.1 Immediate packagings that fall outside the blister and small-unit categories carry the full set of Article 54 particulars.1

Can an EU package leaflet contain promotional content?

No. Article 62 permits symbols or pictograms that clarify information mentioned in Articles 54 and 59(1), and other information compatible with the summary of the product characteristics which is useful for the patient. The same Article excludes any element of a promotional nature from the outer packaging and the leaflet.1 Separately, Article 61(2) requires refusal of the marketing authorisation where the labelling or leaflet departs from the particulars in the summary of product characteristics.1

Is readability testing of the package leaflet mandatory in the EU?

Yes. Article 59(3) requires the package leaflet to reflect the results of consultations with target patient groups, so that it is legible, clear and easy to use.1 The results of those assessments are provided to the competent authority with the mock-ups and the draft leaflet at the time of the marketing authorisation application, under Article 61(1).1

How long does a competent authority have to object to a labelling change?

Article 61(3) sets 90 days for changes to an aspect of the labelling or package leaflet covered by Title V that are not connected with the summary of product characteristics. Where the competent authorities have not opposed the change within 90 days following the introduction of the request, the applicant may put it into effect.1

What is the black symbol on some EU package leaflets?

It marks products included in the list referred to in Article 23 of Regulation (EC) No 726/2004. For those products, Article 59(1) requires the statement “This medicinal product is subject to additional monitoring”, preceded by the black symbol and followed by an appropriate standardised explanatory sentence.1

Must labelling appear in the language of every Member State where a product is sold?

Article 63(1) requires the labelling particulars listed in Articles 54, 59 and 62 to appear in an official language or languages of the Member State of placing on the market, as specified by that Member State. Several languages may be used on the same pack where the same particulars appear in all of them.1 Article 63(3) allows competent authorities to grant a full or partial language exemption where the product is not delivered directly to the patient or where there are severe availability problems.1

Footnotes

  1. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Consolidated version of 2025-01-01. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.